

































latest(developments( in(nanomedicine(particularly( in(the(areas(of(cancer,( infection(and(targeting(of(
the( central( nervous( system( (CNS).( The( primary( objective( of( this( meeting( was( to( share( and(
disseminate(insights(and(experiences(encountered(in(developing(these(novel(medicines.(Secondly,(it(





The( application( of( nanotechnology( to( this( field( has( begun( to( address( this( targeted( approach( and(
been( the( subject( of(many( articles( in( recent( years(with( several( reporting( promising( preclinical( and(
clinical(results.(Throughout(the(conference(a(range(of(technological(approaches(to(targeted(delivery(
were(discussed(including(polymeric(nanoparticles,(selfXassembling(micelles(and(liposomes.((
A( novel( targeting( approach( has( been( taken( by(Dr( Chris( Scott( (Queen’s(University( Belfast)( and( his(
team,(who(reported( that( sialic(acidXdecorated(nanoparticles(were(able( to( target( sialic(acidXbinding(
immunoglobulinXlike( lectins( (siglecs)( to( induce( therapeutically( useful( effects( on( systemic( and(
pulmonary(inflammation(in(murine(models.3(Prof.(Andreas(Schätzlein((UCL(&(Nanomerics)(presented(
work( on(Nanomerics’(Molecular( Envelope( Technology( (MET),(where( nanoparticles( are( engineered(
from( biocompatible( selfXassembling( polymers4.( The( team( have( shown( that( it( is( possible( to(
encapsulate(hydrophobic(drugs(and(peptides,(and(in(turn(generate(stable(nanoparticles(using(MET.((
Most(recently(they(have(used(MET(to(develop(an(orally(active(form(of(Amphotericin(B((AmB).(AmB(is(
a( polyene( antibiotic,( which( is( currently( administered( parenterally( to( treat( fungal( infections( and(
Leishmaniasis5.( ( Being( able( to( deliver( this( antibiotic( orally,( would( overcome( the( major( adverse(
effects( of( parenteral( delivery,( which( is( infusion( related( toxicity.( Other( putative( benefits( of( the(
approach( are( aimed( at( limiting( chronic( toxicities( such( as( nephrotoxicity( and( anaemia.( Utilising(
industry( standard(models( of( visceral( Leishmaniasis,( candidiasis( and( aspergillosis( in( small( animals,(
they(have(been(able(to(show(comparable(efficacy(to(the(current(treatment(of(choice6(–(a(parenteral(
liposomal(AmB((AmBisome®).(Furthermore,(using( industry(standard(models(of( the(disease( in(small(
animals,( results( showed( that( this( new( formulation( provided( an( improved( selective( bioavailability(
with(efficient(uptake(by(the(gastrointestinal(epithelia(and(transport(to(the(lung,(liver(and(spleen.(Dr(
Marianne(Ashford((AstraZeneca,(AZ)(discussed(the(collaboration(between(AZ(and(BIND(Therapeutics,(
where( together( they( are( developing( and( scalingXup( BIND’s( Accurins®( for( application( in( leukaemia(
and( cancer.( The( aim( here( is( to( improve( the( therapeutic( index( of( AZD2811,( a( potent( selective(
inhibitor(of(the(Aurora(B(kinase7.(It(was(also(noted(that(AZ(has(recently(signed(a(license(agreement(
with( Starpharma( around( the( use( of( its( dendrimer( drug( delivery( technology( (DEP™)8( in( the(
development(and(commercialisation(of(an(AZ(compound.(
These( are( just( a( couple( of( examples( of( the( progress( that( is( being( made( in( the( development( of(
targeted( therapeutics( and( it( is( apparent( that( these( have( shown( sufficient( efficacy( in( in# vitro( and(
initial( animal( models( to( warrant( progression( to( the( next( stages( of( the( development( pathway.(




The(process( to( take(a( therapeutic( from(discovery( to( clinic( is( challenging,( long(and(expensive.( This(
work(tends(to(be(undertaken(by(pharmaceutical(companies(and(contract(research(organisations(that(
have( developed( processes,( knowXhow( and( have( the( necessary( supply( chains( that( meet( quality(
assurance( and( regulatory( standards.( Throughout( the( discussion,( regardless( of( the( size( of( the(
company(involved(in(these(initial(stages(in(development,(it(was(apparent(that(it(is(difficult(to(source(
GMP( compliant( polymers( to( provide( a( viable( supply( chain( and( there( is( a( shortage( of( suitable(
excipients,( particularly( for( nucleic( acid( delivery.( There( is( a( need( to( educate( and( inform( contract(
research(and(manufacturing(organisations( (CROs(or(CMOs)(of( the(nanomaterials( and( formulations(
used( in( the(design(of(nanomedicines( in(order( that( this(gap(can(be( filled.( (Given( the(willingness(of(
many(CROs(and(CMOs,( it(was(suggested( that(most(would( rise( to( this(challenge(and(would(happily(
engage(in(this(space.(
Academics(are(now(encouraged(to(deliver(commercial(and(societal(impact(through(their(research,(an(
increasing( number( are( getting( involved( in( development( steps( beyond( the( traditional( proofXofX
concept(stage,(often(referred(to(as(technology(readiness(level((TRL)(3.(Again,(there(was(a(consensus(
that( there( is( a( knowledge( gap( amongst(many( researchers( about( the( requirements( and( processes(
that(are( required( to( take(a( therapeutic( through( further(development(stages.(Dr(Marianne(Ashford(
explained( that( AZ( and( the( University( of( Manchester( have( entered( into( a( strategic( collaboration(
called(The(North(West(Centre(for(Advanced(Drug(Delivery((NoWCADD)(to(help(to(bridge(this(gap(and(
provide(an(arena( through(which(knowledge( transfer(can(occur(between( researchers(and(scientists(
from(the(different(institutions.(The(primary(aim(of(the(centre(is(to(translate(promising(drug(delivery(
concepts( into( valued( medicinal( products( for( cancer( and( other( serious( diseases( that( include(
cardiovascular,( metabolic,( respiratory,( inflammatory( and( autoimmune( diseases.( In( addition,(
NoWCADD(aims(to(support(undergraduate(learning(within(the(Pharmacy(School(and(inspire(the(next(
generation( of( pharmaceutical( scientists.( What( sets( this( collaboration( apart( from( other( similar(
initiatives( is( that( a( lab( scale( manufacturing( and( characterisation( capability( for( advanced( drug(
delivery(technologies(is(being(established(within(the(university.((The(initial(phase(of(funding(is(for(5(
years( and( it( is( anticipated( that( this( will,( with( time,( lead( to( collaborative( relationships( with( other(





established( Translation( Advisory( Board( (TAB)( (www.enatrans.eu/public/services/translationX
advisoryXboard)( that( has( been( established( as( part( of( the( EU( ENATRANS( project( (Enabling(
NAnomedicine(TRANSlation).(The(TAB(constitutes(a( team(of(experts( from(across(Europe( that(have(







intermediate( step,( soXcalled( pilot( scale,( would( allow( production( of( enough( sample( to( supply( the(
needs(of(ongoing(clinical(trials,(whilst(also(demonstrating(that(materials(and(formulations(can(indeed(
be(produced( in( larger(quantities.( Successfully( achieving( this( intermediate( step(does(not,(however,(
ensure(success(at(the(larger(industrial(scale,(but(this(does(provide(an(important(route(for(academics(
to(provide(evidence(that(their(novel(chemistries(can(be(scaled.(To(understand(any(changes(that(may(
occur( to( the( critical( nanomedicine( components( during( the( scaleXup( process,( is( one( of( the( key(
challenges(of(the(industry(and(there(are(companies(who(have(developed(expertise(and(knowXhow(in(
this(space.(The(outcome(from(this(discussion(was(that(researchers(should(be(made(aware(of(what(is(
feasible( and( decision( points( used( during( industrial( scaleXup;( this( will( allow( progress( through( the(
earlier( translational( steps( and( definition( of( processes( that( are( amenable( to( further( development(




employ( the( nonXionic( surfactant( dodecyldimethylamineXNXoxide( to( produce( micelles.( These(
structures(have(been(explored(from(a(formulation(perspective(in(order(to(enhance(the(therapeutic(
index( of( prospective( drug(molecules.( In( order( to( understand,( how( these( structures( form( and( the(
effects(of( the( varying( concentrations( and(physical( properties( in( their( construction,( Prof.( Lawrence(
and(her(team(utilise(smallXangle(neutron(scanning((SANS)(as(a(key(characterisation(tool(in(their(work.((
This( technique( is( not( widely( used( in( the( pharmaceutical( industry,( but( in( these( experiments9( and(
others10( have( shown( that( this( technique( provides( valuable( morphological( information( about( the(
structures(formed(and(the(shape(of(the(drug(carrier;(specifically(highlighting(how(morphologies(are(
affected(with(varying(concentrations(and(physical(conditions.(Other(techniques(that(were(discussed(
included( dynamic( light( scattering( (DLS),( flow( cytometry( and( Izon( Sciences’( qNano( Gold( system.(
Whilst(these(are(all(effective(techniques,(which(certainly(add(to(the(understanding(of(nanomedicine(
discovery( and( development,( there( was( a( general( consensus( that( a( lack( of( standardised(
characterisation( techniques( remains,( particularly( for( bioanalytical( assays( and( that( standardisation(
would(promote(consistency(and(uniformity(within(this(field.((
Prof.( Andrew(Owen( (University( of( Liverpool( &( Chair( of( the( BSNM)( informed( delegates( about( the(




•! To( provide( a( transXdisciplinary( testing( infrastructure( covering( a( comprehensive( set( of(
preclinical( assays( (physical,( chemical,( in(vitro( and( in(vivo( biological( testing),( allowing(
Deleted:'earlier(this(year
researchers( to( fully( characterise( the( biodistribution,(metabolism,( pharmacokinetics,( safety(
profiles(and(immunological(effects(of(their(medicinal(nanoXproducts.(
•! To( foster( the( use( and( deployment( of( standard( operating( procedures( (SOPs),( benchmark(
materials( and( quality( management( for( the( preclinical( characterisation( of( medicinal( nanoX
products.(
•! To( promote( interXsector( and( interdisciplinary( communication( among( key( drivers( of(
innovation,(especially(between(developers(and(regulatory(agencies.(
It( is( anticipated( that( through( this( international( collaborative( approach,( a( defined( set( of(
measurements( and( characterisation( processes( can( be( established( to( support( the( development(
process(for(various(nanomedicines.(This(may(also(avoid(generalisations(and(assumptions(about(these(
formulations( and( materials,( which( can( lead( to( either( false( expectations( or( unnecessary( safety(
concerns11.(Furthermore(it(will(also(help(to(address(concerns(over(the(effectiveness(of(some(animal(
models.( This( was( discussed( particularly( with( respect( to( the( enhanced( permeation( and( retention(
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